Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11427567 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors

Patent 11427567 was granted and assigned to Incyte on August, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Jingwei Li0

Qinda Ye0

Min Ye0

Margaret Favata0

Liangxing Wu0

Ken Mukai0

Wenqing Yao0

Yingnan Chen0

...

Date of Patent

August 30, 2022

Patent Application Number

16992505

Date Filed

August 13, 2020

Patent Citations

US Patent 10308644 Heterocyclic compounds as immunomodulators

0

US Patent 11066404 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors

Patent Citations Received

US Patent 11981671 Bicyclic pyrazolyl amines as CDK2 inhibitors

0

US Patent 11851426 Bicyclic amines as CDK2 inhibitors

0

US Patent 11866432 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors

0

US Patent 11919904 Sulfonylamide compounds as CDK2 inhibitors

0

US Patent 11976073 Bicyclic amines as CDK2 inhibitors

0

Patent Primary Examiner

Charanjit Aulakh

CPC Code

The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11427567 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool